Jefferies Believes Lantheus (NASDAQ: LNTH) Won’t Stop Here

By Carrie Williams

In a report issued on October 10, Raj Denhoy from Jefferies reiterated a Buy rating on Lantheus (NASDAQ: LNTH), with a price target of $22. The company’s shares closed yesterday at $18.70, close to its 52-week high of $20.45.

According to, Denhoy is a 5-star analyst with an average return of 12.8% and a 63.7% success rate. Denhoy covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Varian Medical Systems, and Zimmer Biomet Holdings.

Currently, the analyst consensus on Lantheus is Moderate Buy and the average price target is $22, representing a 17.6% upside.

In a report issued on September 27, Cantor Fitzgerald also assigned a Buy rating to the stock with a $22 price target.

The company has a one-year high of $20.45 and a one-year low of $7.61. Currently, Lantheus has an average volume of 597.5K.

Based on the recent corporate insider activity of 60 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Lantheus Holdings, Inc. engages in the development, manufacture and commercialization of innovative diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. The company products are used by cardiologists, nuclear physicians, radiologists, internal medicine physicians, sonographers and technologists working in a variety of clinical settings. It operates through the following segments: U.S. and International. The U.S. segment produces and markets medical imaging agents and products throughout the U.S. This segment sell its products to radiopharmacies, integrated delivery networks, hospitals, clinics and group practices. The International segment operations consist of production and distribution activities in Puerto Rico and direct distribution activities in Canada. The company was founded in 2007 and is headquartered in North Billerica, MA.